Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.74+0.01 (+0.07%)
Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%
Dr Reddys Laboratories statistics
102 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- –
- Last ex-dividend date
- Jul 24, 2026
- Fundamentals through
- Mar 31, 2026
- Share price as of
- –
Valuation ratiosIndustry
- P/TBV Ratio
- 4.46
- –
- P/OCF Ratio
- 20.36
- –
Enterprise valuationIndustry
- EV / Sales
- 3.63
- –
- EV / EBIT
- 24.15
- –
- EV / FCF
- 36.52
- –
Share statisticsIndustry
- Shares Change (YoY)
- -0.10%
- –
- Float
- 721M
- –
- Shares Held by Insiders
- 13.6%
- –
- Shares Held by Institutions
- 15.1%
- –
Short sellingIndustry
- Short Interest
- 25M
- –
- Short Interest Change
- -3.23%
- –
- Days to Cover
- 7.81
- –
Stock price statisticsIndustry
- Price Change (1 Week)
- -1.14%
- –
- Price Change (1 Month)
- 14.3%
- –
- Price Change (3 Months)
- 21.7%
- –
- Price Change (6 Months)
- 8.30%
- –
- Price Change (YTD)
- 4.99%
- –
- Price Change (1 Year)
- 6.43%
- –
- Price Change (3 Years)
- 12.9%
- –
- Price Change (5 Years)
- 13.3%
- –
- Price Change (10 Years)
- 52.5%
- –
- Average Volume (10 Days)
- 3M
- –
- Average Volume (20 Days)
- 3M
- –
- Average Volume (90 Days)
- 3M
- –
- Relative Volume
- 1.28
- –
- Relative Strength Index (14)
- 69.5
- –
- Volatility (1 Year)
- 26.9%
- –
- Beta (5 Years)
- 0.35
- –
MarginsIndustry
- Pretax Margin
- 16.3%
- –
- EBITDA Margin
- 21.2%
- –
- FCF Margin
- 9.95%
- –
Returns on capitalIndustry
- Return on Equity (ROE)
- 12.1%
- –
- Return on Assets (ROA)
- 7.99%
- –
- Return on Invested Capital (ROIC)
- 9.74%
- –
- Return on Capital Employed (ROCE)
- 12.3%
- –
Financial positionIndustry
- Current Ratio
- 1.80
- –
- Quick Ratio
- 0.70
- –
- Debt / Equity
- 0.21
- –
- Debt / EBITDA
- 1.09
- –
- Debt / FCF
- 2.31
- –
- Net Debt / EBITDA
- 0.87
- –
- Interest Coverage
- 13.52
- –
GrowthIndustry
- Revenue Growth (YoY)
- 3.19%
- –
- Net Income Growth (YoY)
- -24.2%
- –
- EPS Growth (YoY)
- -24.1%
- –
- FCF Growth (YoY)
- 76.6%
- –
- Revenue Growth (3Y CAGR)
- 11.0%
- –
- Revenue Growth (5Y CAGR)
- 12.1%
- –
- EPS Growth (3Y CAGR)
- -1.72%
- –
- EPS Growth (5Y CAGR)
- 19.9%
- –
EfficiencyIndustry
- Asset Turnover
- 0.63
- –
- Inventory Turnover
- 2.15
- –
- WACC
- 7.37%
- –
Income statement (TTM)Industry
- Pretax Income
- ₹54.82B
- –
Balance sheetIndustry
- Net Cash (Debt)
- -₹61.97B
- –
- Net Cash Per Share
- -74.25 INR
- –
- Equity (Book Value)
- ₹377.06B
- –
- Book Value Per Share
- 451.76 INR
- –
- Tangible Book Value
- ₹259.11B
- –
- Working Capital
- ₹134.41B
- –
Cash flow (TTM)Industry
- Capital Expenditures
- -₹23.33B
- –
- FCF Per Share
- 40.05 INR
- –
Dividends and yieldsIndustry
- Earnings Yield
- 3.71%
- –
- FCF Yield
- 2.89%
- –
- Dividend Yield
- 0.58%
- –
- Shareholder Yield
- 0.58%
- –
- Dividend Per Share
- 8.00 INR
- –
- Dividend Growth (YoY)
- 0.00%
- –
- Years of Dividend Growth
- 0
- –
- Payout Ratio
- 15.5%
- –
- FCF Payout Ratio
- 19.9%
- –
Taxes and interestIndustry
- Interest Expense
- ₹3.74B
- –
- Income Tax
- ₹12.35B
- –
- Effective Tax Rate
- 22.5%
- –
Scores and fair valueIndustry
- Graham Number
- 722.95 INR
- –
- Graham Upside
- -47.8%
- –
- Altman Z-Score
- 5.48
- –
- Piotroski F-Score
- 4
- –
- Beneish M-Score
- -2.51
- –
- Lynch Fair Value
- 1024.50 INR
- –
- Lynch Upside
- -26.0%
- –
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RDY | S&P 500 | Difference | RDY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.4% | -3.0% | +18.5 pts | ||
| 3 months | +18.7% | -2.8% | +21.5 pts | ||
| Year to date | +5.7% | +11.5% | −5.8 pts | ||
| 1 year | +7.0% | +13.5% | −6.4 pts | ||
| 3 years | +15.7% | +77.7% | −62.0 pts | +5.0% | +21.1% |
| 5 years | +18.9% | +72.6% | −53.7 pts | +3.5% | +11.5% |
| 10 years | +65.9% | +308.2% | −242.2 pts | +5.2% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
25M RDY shares were sold short on Oct 30, 2026, down 3.2% from the previous report. At recent volumes it would take 7.8 days to buy them back. Over the last 20 sessions, 46.8% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 25,297,771 | -3.2% | 3,240,176 | 7.8 |
| Oct 15, 2026 | 26,141,105 | -7.9% | 3,092,168 | 8.4 |
| Sep 30, 2026 | 28,392,167 | -2.0% | 3,219,978 | 8.8 |
| Sep 15, 2026 | 28,958,755 | +21.2% | 3,214,025 | 9.0 |
| Aug 31, 2026 | 23,897,560 | +6.1% | 2,167,938 | 11.0 |
| Aug 14, 2026 | 22,514,013 | +7.8% | 2,553,333 | 8.8 |
| Jul 31, 2026 | 20,893,009 | -0.4% | 3,041,655 | 6.9 |
| Jul 15, 2026 | 20,975,049 | -9.5% | 2,908,447 | 7.2 |
| Jun 30, 2026 | 23,186,031 | +1.4% | 3,503,267 | 6.6 |
| Jun 15, 2026 | 22,854,885 | +2.1% | 1,365,323 | 16.7 |
| May 29, 2026 | 22,387,669 | +10.9% | 1,707,439 | 13.1 |
| May 15, 2026 | 20,180,379 | +28.4% | 3,554,027 | 5.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?